HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, P. H. Articles by Schoenberg, B. S. Search for Related Content PubMed PubMed Citation Articles by Davis, P. H. Articles by Schoenberg, B. S.

Risk factors for progressive supranuclear palsy

^*Deceased.
Neuroepidemiology Branch (Drs. Davis and Schoenberg), Intramural Research Program, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD; and the Department of Neurology (Drs. Golbe and Duvoisin), University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, and the Neurology Service, Robert Wood Johnson University Hospital, New Brunswick, NJ.

To explore possible risk factors for progressive supranuclear palsy (PSP), we conducted a case-control study of 50 cases in New Jersey. Two neurologists confirmed the diagnosis in the 41 living patients. Two hospital controls were matched by age, sex, race, date of death, and relationship of next-to-kin to each case. A structured interview was administered in person to the next-of-kin of cases and controls. Genetic, viral, toxic, medical, surgical, and personality factors were investigated. Cases lived in areas with low population as adults significantly more frequently than controls. The study identified no other factors associated with PSP including a history of stroke, hypertension, or smoking.

Address correspondence and reprint requests to Dr. Davis, Room 5E-20, VA Medical Center, 510 East Stoner Avenue, Shreveport, LA 71101–4295.

Dr. Davis was supported by a fellowship from the Medical Research Council of Canada.

Presented in part at the thirty-ninth annual meeting of the American Academy of Neurology, New York, NY, April 1987.

Received October 2, 1986. Accepted for publication in final form March 18, 1988.

This article has been cited by other articles:

				H U Rehman Progressive supranuclear palsy Postgrad. Med. J., June 1, 2000; 76(896): 333 - 336. [Abstract] [Full Text]

				N. Vanacore, V. Bonifati, G. Fabbrini, C. Colosimo, R. Marconi, D. Nicholl, U. Bonuccelli, F. Stocchi, P. Lamberti, G. Volpe, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy Neurology, January 11, 2000; 54(1): 114 - 114. [Abstract] [Full Text] [PDF]

				H. R Morris, N. W Wood, and A. J Lees Classic diseases revisited: Progressive supranuclear palsy (Steele-Richardson-Olszewski disease) Postgrad. Med. J., October 1, 1999; 75(888): 579 - 584. [Abstract] [Full Text]

				A. Rojo, R. S. Pernaute, A. Fontan, P. G. Ruiz, J. Honnorat, T. Lynch, S. Chin, I. Gonzalo, A. Rabano, A. Martinez, et al. Clinical genetics of familial progressive supranuclear palsy Brain, July 1, 1999; 122(7): 1233 - 1245. [Abstract] [Full Text] [PDF]

				G. Fabbrini, N. Vanacore, V. Bonifati, C. Colosimo, G. Meco, for the Study Group on Atypical Parkinsonisms, and J. Ghika Presymptomatic Hypertension in Progressive Supranuclear Palsy Arch Neurol, August 1, 1998; 55(8): 1153 - 1155. [Full Text] [PDF]